港股異動丨昊海生物科技(6826.HK)續跌4.6% 近日自高位回撤達20%
格隆匯6月10日丨此前創歷史新高的昊海生物科技(6826.HK)近日連續回調達20%,現跌4.6%,報82港元,總市值303億港元。昊海生物A股亦小幅下跌。港交所權益資料顯示,昊海生物科技H股被摩根大通06月01日在場內以每股平均價99.633港元減持22.60萬股,涉資約2251.71萬港元。另外,股東樓國樑因自身資金需要,通過集中競價方式,在6月24日至12月21日期間,減持公司不超過216.5萬股A股股份。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.